In an aggressive Hoxa9 and Meis1 (H9M)-dependent murine AML model that recapitulates human disease, FGB-assisted multiplex assays readily allowed for the assessment of the competitive behavior of polyclonal H9M AML samples during leukemogenesis, drug exposure and miRNA challenge [15]. This evidence concerns the gene MEIS1 and acute myeloid leukemia.